A response by Strauss et al. to "a comment on the comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia".

Autor:	Strauss WE; AMAG Pharmaceuticals, Inc, Waltham, Massachusetts., Franklin Adkinson N; Johns Hopkins University School of Medicine, University in Baltimore, Baltimore, Maryland., Macdougall IC; Department of Renal Medicine, King's College Hospital, London, United Kingdom., Auerbach M; Auerbach Hematology and Oncology, Baltimore, Maryland., Kaper RF; AMAG Pharmaceuticals, Inc, Waltham, Massachusetts., Chertow GM; Stanford University School of Medicine, Stanford, California., Krop JS; AMAG Pharmaceuticals, Inc, Waltham, Massachusetts.
Jazyk:	angličtina
Zdroj:	American journal of hematology [Am J Hematol] 2018 Sep; Vol. 93 (9), pp. E232-E233. Date of Electronic Publication: 2018 Aug 06.
DOI:	10.1002/ajh.25200
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text